{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:48:38Z","timestamp":1782535718408,"version":"3.54.5"},"reference-count":39,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Eosinophilic esophagitis (EoE) is a chronic inflammatory and an immune-mediated condition diagnosed based on both clinical and pathologic findings. EoE has been identified as one of the leading causes of esophageal dysfunction worldwide. If untreated, EoE often\n follows a progressive course that leads to fibrosis and esophageal stricture and perforation. The use of biologic therapies that target specific pathways will help us understand the essential pathophysiologic steps in EoE, in addition to providing symptomatic treatment. In this narrative review,\n we review the potential targeted therapies of these cells and related pathways, the evidence of therapeutic benefit, and suggestions for future therapeutic approaches. An updated review of treatment options is necessary given deeper understanding of the pathogenesis and more recent advances\n in treatment since the consensus recommendations published in 2016.\n                    <jats:bold>Objective:<\/jats:bold>\n                    We sought to review the contemporary data with regard to treatment approaches in EoE, particularly through immune-modulating therapeutic approaches.\n                    <jats:bold>Methods:<\/jats:bold>\n                    The MEDLINE (PubMed)\n data base was queried by using specified search terms. Articles were selected based on their contribution to the understanding of how therapeutics for EoE, particularly those that modulate immunity play a role in the management of this disease.\n                    <jats:bold>Results:<\/jats:bold>\n                    Among immune-modulating\n therapies for EoE, anti\u2010interleukin (IL) 5\/IL-5 Receptor (R) \u03b1 and anti\u2010IL-13\/IL-4 Receptor (R) \u03b1 therapies have the most accumulated clinical trial and safety data at this time. Other emerging immunologic targets that warrant discussion include thymic stromal lymphopoietin\n and Sialic acid-binding IG-like lectin 8 (Siglec-8). Furthermore, the contribution of fibroblasts and myofibroblasts to the pathogenesis of EoE also provides many potential therapeutic targets. Allergen-specific immunotherapies have shown variable benefit in the treatment of EoE.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Immune-modulating therapies seem to be a promising avenue of the treatment of EoE; both established and emerging targets of therapy exist to manage this condition.\n                  <\/jats:p>","DOI":"10.2500\/aap.2026.47.260020","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:42:02Z","timestamp":1777437722000},"page":"170-176","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of eosinophilic esophagitis with immune modulating agents"],"prefix":"10.2500","volume":"47","author":[{"given":"Neha","family":"Pancholy","sequence":"first","affiliation":[{"name":"From the Wayne Memorial Community Health Centers, Department of Internal Medicine\/Primary Care, Tafton, Pennsylvania and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisoo","family":"Ghaffari","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.14309\/ajg.0000000000003194","article-title":"ACG clinical guideline: diagnosis and management of eosinophilic esophagitis","volume":"120","author":"Dellon","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","article-title":"Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age","volume":"390","author":"Chehade","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"crossref","first-page":"EVIDoa2500095","DOI":"10.1056\/EVIDoa2500095","article-title":"Cendakimab in adults and adolescents with eosinophilic esophagitis","volume":"4","author":"Dellon","year":"2025","journal-title":"NEJM Evid"},{"key":"B6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa\u2019ad","year":"2011","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2313318","article-title":"Eosinophil depletion with benralizumab for eosinophilic esophagitis","volume":"390","author":"Rothenberg","year":"2024","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.14309\/01.ajg.0000858424.48968.ad","article-title":"Results from KRYPTOS, a phase 2\/3 study of lirentelimab (AK002) in adults and adolescents with EoE","volume":"117","author":"Dellon","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"B11","first-page":"1","article-title":"Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring","volume":"30","author":"Collins","year":"2017","journal-title":"Dis Esophagus"},{"key":"B12","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/apt.12413","article-title":"Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis","volume":"38","author":"Dellon","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41687-017-0006-5","article-title":"Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension","volume":"1","author":"Hudgens","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jaip.2022.02.049","article-title":"Novel questionnaires for assessing signs and symptoms of eosinophilic esophagitis in children","volume":"10","author":"Kamat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/gutjnl-2011-301817","article-title":"Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system","volume":"62","author":"Hirano","year":"2013","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2022.10.026","article-title":"Breaking down the complex pathophysiology of eosinophilic esophagitis","volume":"130","author":"Underwood","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaci.2012.10.057","article-title":"Eosinophilic gastrointestinal disease suggestive of pathogenesis-related class 10 (PR-10) protein allergy resolved after immunotherapy","volume":"131","author":"De Swert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.anai.2025.05.016","article-title":"Future of therapy and monitoring for eosinophilic esophagitis and eosinophilic gastrointestinal diseases","volume":"135","author":"Dickerson","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B19","article-title":"Dupixent (dupilumab) [package insert]"},{"key":"B20","article-title":"Eohilia [package insert]"},{"key":"B21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Ebina-Shibuya","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"815842","DOI":"10.3389\/fphys.2021.815842","article-title":"Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets","volume":"12","author":"Racca","year":"2021","journal-title":"Front Physiol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid\u2013binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jaci.2024.04.006","article-title":"Development and dysfunction of structural cells in eosinophilic esophagitis","volume":"153","author":"Laky","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2024.11.028","article-title":"Eosinophilic esophagitis drives tissue fibroblast regenerative programs toward pathologic dysfunction","volume":"155","author":"Jumabay","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B26","first-page":"461","article-title":"Differential contributions of fibroblast subpopulations to intercellular communication in eosinophilic esophagitis","volume":"13","author":"Li","year":"2024","journal-title":"Biology (Basel)"},{"key":"B27","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2020.07.035","article-title":"Increased production of LIGHT by T cells in eosinophilic esophagitis promotes differentiation of esophageal fibroblasts toward an inflammatory phenotype","volume":"159","author":"Manresa","year":"2020","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41385-022-00486-y","article-title":"The LIGHT switch: mechanisms of fibroblast pathology in eosinophilic esophagitis","volume":"15","author":"Chua","year":"2022","journal-title":"Mucosal Immunol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"C1079","DOI":"10.1152\/ajpcell.00285.2019","article-title":"Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73)","volume":"317","author":"Minor","year":"2019","journal-title":"Am J Physiol Cell Physiol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1016\/j.celrep.2019.02.101","article-title":"Colonic CD90+ crypt fibroblasts secrete semaphorins to support epithelial growth","volume":"26","author":"Karpus","year":"2019","journal-title":"Cell Rep"},{"key":"B31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000543022","article-title":"Epidemiology of eosinophilic esophagitis: really a novel and evolving disease?","volume":"10","author":"Mona","year":"2025","journal-title":"Inflamm Intest Dis"},{"key":"B32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2500\/aap.2022.43.220014","article-title":"Current and emerging therapies for eosinophilic esophagitis","volume":"43","author":"Sher","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"B33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.anai.2020.03.020","article-title":"AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis","volume":"124","author":"Hirano","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jaci.2013.04.053","article-title":"Eosinophilic esophagitis treated with immunotherapy to dust mites","volume":"132","author":"Ramirez","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.anai.2014.08.004","article-title":"Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis","volume":"113","author":"Lucendo","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/imt.14.3","article-title":"Immunotherapeutic approaches for the treatment of eosinophilic esophagitis","volume":"6","author":"Cianferoni","year":"2014","journal-title":"Immunotherapy"},{"key":"B37","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1053\/j.gastro.2014.02.006","article-title":"Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis","volume":"146","author":"Arias","year":"2014","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.cgh.2023.03.006","article-title":"Development of a practical guide to implement and monitor diet therapy for eosinophilic esophagitis","volume":"21","author":"Chang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaci.2010.04.037","article-title":"Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis","volume":"126","author":"Sherrill","year":"2010","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000003\/art00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:44:40Z","timestamp":1782535480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.260020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,1]]}},"alternative-id":["1088-5412(20260501)47:3L.170;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.260020","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}